Trademark Overview
On Wednesday, January 29, 2025, a trademark application was filed for XOFLX with the United States Patent and Trademark Office. The USPTO has given the XOFLX trademark a serial number of 79417533. The federal status of this trademark filing is NON-FINAL ACTION COUNTED - NOT MAILED as of Thursday, July 10, 2025. This trademark is owned by Oxford Genetics Ltd. The XOFLX trademark is filed in the Chemical Products, Pharmaceutical Products, and Computer & Software Services & Scientific Services categories with the following description:
Chemical and biological reagents for medical and veterinary use; diagnostic and test reagents for medical and veterinary use; human and animal cells and parts thereof for medical and veterinary purposes; microorganisms for medical and veterinary purposes; viral vectors for medical and veterinary purposes; lentiviruses, lentivirus particles and lentivirus plasmids, all for medical and veterinary use.
Chemical and biological substances for use in science and industry; nucleic acids; nucleic recombinant acids, synthetic deoxyribonucleic acids; chemical and biological reagents for non-medical purposes; chemical and biological reagents for scientific and research purposes; human and animal cells and parts thereof for non-medical purposes; microorganisms for non-medical purposes; human and animal cells and parts thereof for scientific and research purposes; microorganisms for scientific and research purposes; viral vectors for use in science and industry; lentiviruses, lentivirus particles and lentivirus plasmids, all for scientific and research purposes.
Design services relating to the creation and alteration of chemical and biological reagents; design services relating to the creation and alteration of nucleic recombinant acids and synthetic deoxyribonucleic acids; design services relating to the creation and alteration of recombinant viruses; design services relating to the creation and alteration of lentiviruses, lentivirus particles and lentivirus plasmids; research, development and bioengineering services relating to lentiviruses; drug discovery services; design services relating to the creation and alteration of cell lines, elementary cells and parts thereof; design services relating to the creation and alteration of viral vectors; information and advice relating to all the aforesaid services.
